Repare Therapeutics Inc.

NasdaqGS:RPTX Stock Report

Market Cap: US$48.5m

Repare Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:RPTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Mar 25SellUS$24,144Lloyd SegalIndividual21,179US$1.14
13 Mar 25SellUS$6,397Michael ZindaIndividual5,611US$1.14
13 Mar 25SellUS$4,099Maria KoehlerIndividual3,596US$1.14
13 Mar 25SellUS$4,331Philip HermanIndividual3,799US$1.14
13 Mar 25SellUS$2,037Daniel BelangerIndividual1,787US$1.14
12 Mar 25SellUS$24,144Lloyd SegalIndividual21,179US$1.14
12 Mar 25SellUS$4,099Maria KoehlerIndividual3,596US$1.14
12 Mar 25SellUS$7,848Steve ForteIndividual6,884US$1.14
12 Mar 25SellUS$6,397Michael ZindaIndividual5,611US$1.14
27 Jan 25SellUS$147,817MPM BioImpact LLCCompany120,246US$1.28
27 Jan 25SellUS$108,088BioImpact Capital LLCCompany87,927US$1.28
15 Jan 25SellUS$396,974MPM BioImpact LLCCompany294,080US$1.44
15 Jan 25SellUS$290,275BioImpact Capital LLCCompany215,037US$1.44
03 Jan 25SellUS$487,440MPM BioImpact LLCCompany371,026US$1.38
03 Jan 25SellUS$356,421BioImpact Capital LLCCompany271,298US$1.38
23 Dec 24SellUS$611,458MPM BioImpact LLCCompany335,966US$1.82
23 Dec 24SellUS$447,107BioImpact Capital LLCCompany245,663US$1.82

Insider Trading Volume

Insider Buying: RPTX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of RPTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders457,8311.08%
General Public8,868,27620.9%
VC/PE Firms9,412,80422.1%
Hedge Funds10,333,60024.3%
Institutions13,438,19731.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 77.29% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.3%
BVF Partners L.P.
10,333,600US$11.8m0%0.45%
8.1%
CHI Advisors LLC
3,443,659US$3.9m2.11%2.46%
7.93%
Blue Owl Capital Holdings LP
3,372,499US$3.8m0%no data
7.82%
OrbiMed Advisors LLC
3,322,488US$3.8m0%0.06%
6.23%
Versant Venture Management, LLC
2,646,657US$3.0m0%1.34%
4.7%
ARK Investment Management LLC
1,999,997US$2.3m-20.3%0.02%
4.51%
Redmile Group, LLC
1,916,089US$2.2m-1.36%0.15%
3.04%
Aquilo Capital Management, LLC
1,293,715US$1.5m30.8%2.88%
2.64%
MPM BioImpact LLC
1,121,318US$1.3m-61.5%0.17%
1.93%
BioImpact Capital LLC
819,924US$934.7k-41.2%100.0%
1.11%
Acadian Asset Management LLC
472,102US$538.2k5.48%no data
0.82%
Renaissance Technologies LLC
347,460US$396.1k-23.4%no data
0.49%
Maria Koehler
209,663US$239.0k4.95%no data
0.46%
Morgan Stanley, Investment Banking and Brokerage Investments
193,508US$220.6k-1.69%no data
0.44%
Medical Strategy GmbH, Asset Management Arm
187,057US$213.2k0%0.01%
0.4%
Millennium Management LLC
170,959US$194.9k65.5%no data
0.33%
BlackRock, Inc.
142,311US$162.2k-0.73%no data
0.33%
Lloyd Segal
139,102US$158.6k17.1%no data
0.28%
GSA Capital Partners LLP
117,296US$133.7k-51.2%0.01%
0.27%
Nikko Asset Management Co., Ltd.
116,249US$132.5k-76.7%no data
0.26%
Goldman Sachs Group, Investment Banking and Securities Investments
110,906US$126.4k0%no data
0.25%
BMO Asset Management Corp.
105,241US$120.0k-0.01%no data
0.24%
Affinity Asset Advisors, LLC
100,000US$114.0k-42.3%0.02%
0.21%
Stifel Asset Management Corp.
89,500US$102.0k73.1%no data
0.2%
JPMorgan Chase & Co, Brokerage and Securities Investments
85,802US$97.8k2,140,000%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 05:32
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Repare Therapeutics Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Timothy ChiangCapital One Securities, Inc.
Chris ShibutaniGoldman Sachs